Skin Cancer and Hyperthermia and Radiotherapy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorKantonsspital Winterthur KSW
About this trial
The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).
Eligibility criteria
Qualifiers
Personally signed and dated written informed consent
Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of any differentiation
≥ T2 (TNM Classification 8th Edition)
Tumor thickness up to 2cm (Maximum Depth invasion and/or exophytic growth, measured on pathology report or imaging)
Disqualifiers
Other histology than BCC or SCC
T1 tumor and/or N+ (according to TNM classification 8th edition)
Tumors after resection (R1 or R2 as well as adjuvant indication)
Tumor invasion into critical areas
Trial design
Treatments tested in this trial
- Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined
- Radiotherapy (RT)
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Kantonsspital Winterthur KSW
Lead sponsor
Luzerner Kantonsspital
Collaborator
Lindenhofgruppe AG
Collaborator
Kantonsspital Aarau
Collaborator
Source ClinicalTrials.gov